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Introduction
The Canadian Breast Cancer Research Initiative (CBCRI)
sponsored its second ‘Reasons For Hope’ Conference,
3–5 May 2001, in Quebec City. This gathering brought
together researchers, clinicians, healthcare providers and
advocates to present and discuss some of the latest find-
ings in breast cancer research, diagnosis and treatment.
The multidisciplinary objective of the meeting’s organizers
was clearly illustrated by the initial reports from the
CBCRI’s recently instituted ‘Streams of Excellence’
program, which has brought together teams of
researchers from across Canada to tackle large scale pro-
jects in a thorough and comprehensive manner. For
example, Tim Whelan (McMaster University, Hamilton,
Ontario, Canada) and Irene Andrulis (Lunenfeld Institute,
Toronto, Ontario, Canada) outlined their group’s concep-
tual framework for accelerating the discovery of clinically
relevant molecular changes in breast cancer and rapidly
translating these findings into novel treatment paradigms.
Michael Pollak (Jewish General Hospital, Montreal,
Quebec, Canada) and his group are taking a similar
approach as it specifically relates to insulin-like growth
factors in breast cancer development and progression.
Both of these programs, and other CBCRI-funded ven-
tures, have strong basic research components. The follow-
ing is a sampling of the basic research highlights from this
meeting.
Genetics versus epigenetics in breast cancer
progression
In a plenary session entitled ‘Genetic Approaches to
Understanding the Conversion of Normal to Malignant
Cells’, Phil Leder (Harvard Medical School, Boston, MA,
USA) and Mina Bissell (Berkeley National Laboratory,
Berkeley, CA, USA) presented data and persuasive argu-
ments for the importance of genetic and epigenetic
change, respectively, in breast tumorigenesis. Leder’s lab-
oratory pioneered the use of transgenic mice to identify
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the functional consequences of combinatorial oncogene
overexpression in the mammary gland. This group has
more recently used single oncogenes as genetic ‘initia-
tors’ followed by mouse mammary tumor virus infection as
an ‘accelerator’ to identify cooperativity between genetic
pathways. Using this approach, they have demonstrated
that FGF-3 and Wnt signaling, both of which normally reg-
ulate three-dimensional morphogenesis in the mammary
gland, act cooperatively in progression to true malignancy.
Bissell’s laboratory has taken a very different approach.
After first demonstrating that the tissue microenvironment
regulates the emergence of the malignant phenotype,
regardless of the genetic changes involved, the group has
recently identified the molecular mediators of this epige-
netic regulation. Bissell and her colleagues have now
shown that cellular interactions with the extracellular matrix
influence growth factor signaling, apoptotic pathways,
nuclear structure and transcriptional activity. Importantly,
the appropriate modulation of these epigenetic outputs
occurs only when the three-dimensional architecture of
the breast tissue is maintained.
As most pathologists are quick to point out, alterations in
tissue architecture are a fundamental component of breast
tumor staging. It is thus not surprising pathologists such as
Olli Kallioniemi (National Institutes of Health, Bethesda,
MD, USA) and Peter Watson (University of Manitoba, Win-
nipeg, Manitoba, Canada) have started to capitalize on the
basic findings of researchers such as Leder and Bissell in
their quest to identify the molecular cascades that regulate
clinical breast tumor development. After first pointing out
the inherent difficulties in assessing the masses of data
being generated by gene profiling, Kallioniemi described
the powerful potential of ‘tissue chips’. In this procedure,
serial sections of tissue are arrayed as the solid phase,
which can then be probed for genetic or epigenetic
changes. This technique allows precise correlations to be
made between altered gene expression and specific archi-
tectural changes within heterogeneous tumor samples. As
a proof of principle, Kallioniemi used fluorescent in situ
hydridization to link erbB2 amplification with specific
changes in tumor grade, a technique he called ‘Fish’ on
‘Chips’. Watson, who maintains one of Canada’s largest
and most comprehensive breast tumor banks, has used
microdissection together with array profiling to identify
genes whose altered expression is associated with specific
aspects of breast tumor progression. A number of these
genes, and the biological functions of their products, were
specifically reported on by other members of Watson’s
group throughout the meeting. These included psoriasin
(S100A7), a calcium binding protein that interacts with
centrosomal proteins and is upregulated in ductal carci-
noma in situ; the hypoxia-regulated gene carbonic anhy-
drase IX, which is overexpressed in necrotic tumors; and
the small leucine-rich proteoglycan lumican, which is
upregulated in the stroma of invasive tumors. One conclu-
sion that could thus be reached from observing this stimu-
lating session is that genetic and epigenetic changes prob-
ably intersect at the microenvironmental level to facilitate
architectural changes that ultimately result in the emer-
gence of the malignant phenotype.
Microenvironmental mediators of breast
cancer progression
The characterization of structural, growth factor and sig-
naling molecules that facilitate microenvironmental change
in the normal and malignant breast was a theme that cut
across many sessions at the meeting. At the level of tissue
structure, Dale Laird (University of Western Ontario,
London, Ontario, Canada) has demonstrated that gap
junctional subtypes may play a role in the functional segre-
gation of the myoepithelial and luminal epithelial compart-
ments in the normal mammary gland and that the loss of
these structures plays a role in breast tumor progression.
In an interesting twist, however, Laird’s latest data indicate
that forced expression of gap junctional connexin proteins
in aggressive tumor lines does not lead to functional com-
munication, at least in two-dimensional monolayer culture.
Instead, the connexins were targeted to the lysosomal
pathway for degradation in these cells. Despite this novel
and potentially significant in vitro finding, connexin expres-
sion did decrease the tumorigenicity of these cells in vivo,
which led Laird to speculate that the tumor microenviron-
ment may facilitate transitory channel formation that could
affect cell–cell adhesion.
Decreased adhesion between cells probably facilitates
migration at the invasive front of malignant tumors. One
microenvironmental factor that can initiate such a
decrease in cell–cell adhesion, at least transiently, is hepa-
tocyte growth factor (HGF). HGF is normally produced in
the mammary stroma and acts in a paracrine fashion to
stimulate epithelial ductal morphogenesis by activating the
c-Met tyrosine kinase receptor. Interestingly, Bruce Elliott
(Queens University, Kingston, Ontario, Canada) has
shown that HGF can act as an autocrine factor at the inva-
sive front in mammary tumors and has presented new data
implicating c-src tyrosine kinase signaling in this process.
Specifically, it appears that c-src activity, which is com-
monly upregulated in breast tumors, impinges on STAT-3
signaling to increase HGF expression. The chronic upreg-
ulation of c-src activity in breast tumors has a strong epi-
genetic component. For example, work from Donald Fujita
(University of Calgary, Calgary, Alberta, Canada) indicates
that the protein tyrosine phosphatase 1B upregulates c-
src activity by dephosphorylating the negative regulatory
C-terminal Tyr530 residue of the kinase molecule.
Morag Park’s group (McGill University, Montreal, Quebec,
Canada) has identified a number of signaling events that
contribute to the morphogenic responses elicited by the
HGF-mediated activation of the c-Met receptor. At thisBreast Cancer Research    Vol 3 No 6 Roskelley
meeting, Hanane Khoury (from Park’s group) presented
data demonstrating that a constitutively active form of the
ErbB2 receptor tyrosine kinase disrupts cell–cell junctions
and initiates an invasive program by coopting pathways
that are also utilized by c-Met. Specifically, the oncogenic
form of ErbB2 acts via the Gab1 docking protein to initiate
a sustained activation of Erk signaling that is necessary for
cell junction disruption. Interestingly, this does not occur
when the regulatable wild-type ErbB2 receptor is tran-
siently activated. These data go a long way towards recon-
ciling the apparently paradoxical finding that ErbB2
signaling plays critical roles in both differentiative alveolar
morphogenesis and neoplastic progression in the breast.
Coupling findings such as these together with the combi-
natorial signaling pathway data being generated by labora-
tories such as that of Bill Muller (McMaster University,
Hamilton, Ontario, Canada) will contribute greatly to the
development of the second generation of rational
chemotherapeutic agents that is being accelerated by the
significant, but still limited, success of the upstream ErbB
receptor modulators.
Finally, Evelyn Voura, who is working in the laboratory of
Rama Khokha (Ontario Cancer Institute, Toronto, Ontario,
Canada), used an elegant in vitro tissue reconstitution
approach to show that focal proteolysis initiated by the
action of microenvironmentally regulated matrix metallopro-
teases facilitates the migration of breast tumor cells across
endothelial cell membranes. This transendothelial migration
is a critical step in tumor extravasation. Specifically target-
ing this process may therefore lead to the development of
another class of rational therapeutic tools that could be
used in combination anti-proliferative and anti-migratory
therapies to halt the progression of invasive carcinomas
attempting to leave the primary tumor — the ultimate archi-
tectural disruption that signals the onset of metastasis.
Conclusion
This meeting offered an interesting mix of basic, translational
and clinical research. As many investigators presented
overviews as well as their latest findings, I found that many
sessions gave me an appreciation, in some depth, for topics
outside my specific field. In addition, it was clear from the
data presented that the CBCRI has been successful in fos-
tering meaningful multidisciplinary interactions across fields
— an accomplishment that is certain to improve breast
cancer prevention, diagnosis and treatment.
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